TW202116800A - 多反應性降低之抗hiv疫苗抗體 - Google Patents

多反應性降低之抗hiv疫苗抗體 Download PDF

Info

Publication number
TW202116800A
TW202116800A TW109123108A TW109123108A TW202116800A TW 202116800 A TW202116800 A TW 202116800A TW 109123108 A TW109123108 A TW 109123108A TW 109123108 A TW109123108 A TW 109123108A TW 202116800 A TW202116800 A TW 202116800A
Authority
TW
Taiwan
Prior art keywords
substitution
receptor
antigen
residue
asp
Prior art date
Application number
TW109123108A
Other languages
English (en)
Chinese (zh)
Inventor
史都華 Ａ 席維斯
米切 努山茲維
珍妮佛 姬菲
帕蜜拉 Ｊ 必喬曼
Original Assignee
美國洛克菲勒大學
美國加州工藝技術協會
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美國洛克菲勒大學, 美國加州工藝技術協會 filed Critical 美國洛克菲勒大學
Publication of TW202116800A publication Critical patent/TW202116800A/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C07K16/1145—Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • AIDS & HIV (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TW109123108A 2019-07-08 2020-07-08 多反應性降低之抗hiv疫苗抗體 TW202116800A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962871393P 2019-07-08 2019-07-08
US62/871,393 2019-07-08

Publications (1)

Publication Number Publication Date
TW202116800A true TW202116800A (zh) 2021-05-01

Family

ID=74114255

Family Applications (1)

Application Number Title Priority Date Filing Date
TW109123108A TW202116800A (zh) 2019-07-08 2020-07-08 多反應性降低之抗hiv疫苗抗體

Country Status (9)

Country Link
US (2) US12459990B2 (cg-RX-API-DMAC10.html)
EP (1) EP3997119A4 (cg-RX-API-DMAC10.html)
JP (2) JP7700093B2 (cg-RX-API-DMAC10.html)
KR (1) KR20220047977A (cg-RX-API-DMAC10.html)
CN (1) CN114641488B (cg-RX-API-DMAC10.html)
AU (1) AU2020311902A1 (cg-RX-API-DMAC10.html)
CA (1) CA3146372A1 (cg-RX-API-DMAC10.html)
TW (1) TW202116800A (cg-RX-API-DMAC10.html)
WO (1) WO2021007285A1 (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240279331A1 (en) * 2021-06-11 2024-08-22 The Regents Of The University Of California Antibodies that stimulate nk cell-mediated cytotoxicity
WO2024097957A1 (en) * 2022-11-03 2024-05-10 Duke University Novel antibodies for hiv and methods of making and using the same

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013090644A2 (en) 2011-12-13 2013-06-20 California Institute Of Technology Anti-hiv antibodies having increased potency and breadth
WO2014205491A1 (en) * 2013-06-25 2014-12-31 Monash University Biological molecules and methods of use
US20180028658A1 (en) 2015-02-16 2018-02-01 New York Blood Center, Inc. Antibody-drug conjugates for reducing the latent hiv reservoir
WO2016149695A1 (en) 2015-03-19 2016-09-22 Duke University HIV-1 NEUTRALIZING ANTIBODIES AND USES THEREOF (CD4bs ANTIBODIES)
AU2016249404B2 (en) * 2015-04-17 2021-01-21 Igm Biosciences, Inc. Multi-valent human immunodeficiency virus antigen binding molecules and uses thereof
JP6732915B2 (ja) 2015-12-15 2020-07-29 ギリアード サイエンシーズ， インコーポレイテッド ヒト免疫不全ウイルス中和抗体
EP3601334A4 (en) * 2017-03-27 2021-03-31 The Wistar Institute Of Anatomy And Biology Dna antibody constructs for use against hiv
IL317993B2 (en) * 2018-07-03 2025-11-01 Gilead Sciences Inc Antibodies directed against HIV gp120 and methods of use

Also Published As

Publication number Publication date
JP2022539877A (ja) 2022-09-13
CN114641488A (zh) 2022-06-17
EP3997119A4 (en) 2023-11-22
AU2020311902A1 (en) 2022-01-27
JP2025011201A (ja) 2025-01-23
US20260022162A1 (en) 2026-01-22
WO2021007285A1 (en) 2021-01-14
JP7700093B2 (ja) 2025-06-30
US20220289829A1 (en) 2022-09-15
KR20220047977A (ko) 2022-04-19
EP3997119A1 (en) 2022-05-18
US12459990B2 (en) 2025-11-04
CA3146372A1 (en) 2021-01-14
CN114641488B (zh) 2026-03-20

Similar Documents

Publication Publication Date Title
US11987617B2 (en) Antibodies that target HIV GP120 and methods of use
US12195524B2 (en) Multi-specific antigen binding molecules targeting HIV and methods of use
US20260022162A1 (en) Anti-hiv vaccine antibodies with reduced polyreactivity
TW202110481A (zh) 鑑別對使用gp120 v3聚醣導向之抗體的治療敏感之hiv病患的方法
HK40067703A (en) Anti-hiv vaccine antibodies with reduced polyreactivity
HK40098397A (en) Antibodies that target hiv gp120 and methods of use
BR112020025721B1 (pt) Anticorpos que têm como alvo a gp120 do hiv e composições farmacêuticas
EA048133B1 (ru) АНТИТЕЛА, КОТОРЫЕ НАЦЕЛЕНЫ НА ГЛИКОПРОТЕИН gp120 ВИРУСА ИММУНОДЕФИЦИТА ЧЕЛОВЕКА (ВИЧ), И СПОСОБЫ ИХ ПРИМЕНЕНИЯ